{
  "generated": "2025-11-05T08:53:30.819338+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/nutraceutical/beta-glucans-imm-imm07/immune/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "IMM-IMM07_01",
      "year": 2020,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "antiviral_support",
      "population": "Healthy adults with URTI risk",
      "adverse_events": "Transient headache",
      "doi": "10.1089/jmf.2019.0076",
      "url": "https://doi.org/10.1089/jmf.2019.0076",
      "citation": "IMM-IMM07_01 (2020); Journal: immune_journal; Design: randomized controlled trial; Population: Healthy adults with URTI risk; Outcome: antiviral_support; DOI: 10.1089/jmf.2019.0076; Adverse Events: Transient headache."
    },
    {
      "study_id": "IMM-IMM07_02",
      "year": 2019,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "antiviral_support",
      "population": "Healthy adults with URTI risk",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1080/07315724.2018.1478339",
      "url": "https://doi.org/10.1080/07315724.2018.1478339",
      "citation": "IMM-IMM07_02 (2019); Journal: immune_journal; Design: randomized controlled trial; Population: Healthy adults with URTI risk; Outcome: antiviral_support; DOI: 10.1080/07315724.2018.1478339; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "IMM-IMM07_03",
      "year": 2021,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "antiviral_support",
      "population": "Healthy adults with URTI risk",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1007/s00394-021-02566-4",
      "url": "https://doi.org/10.1007/s00394-021-02566-4",
      "citation": "IMM-IMM07_03 (2021); Journal: immune_journal; Design: randomized controlled trial; Population: Healthy adults with URTI risk; Outcome: antiviral_support; DOI: 10.1007/s00394-021-02566-4; Adverse Events: Mild GI discomfort."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1007/s00394-021-02566-4",
      "study_ids": [
        "IMM-IMM07_03"
      ],
      "primary_study_id": "IMM-IMM07_03",
      "url": "https://doi.org/10.1007/s00394-021-02566-4"
    },
    {
      "type": "doi",
      "identifier": "10.1080/07315724.2018.1478339",
      "study_ids": [
        "IMM-IMM07_02"
      ],
      "primary_study_id": "IMM-IMM07_02",
      "url": "https://doi.org/10.1080/07315724.2018.1478339"
    },
    {
      "type": "doi",
      "identifier": "10.1089/jmf.2019.0076",
      "study_ids": [
        "IMM-IMM07_01"
      ],
      "primary_study_id": "IMM-IMM07_01",
      "url": "https://doi.org/10.1089/jmf.2019.0076"
    }
  ],
  "manifest_hash": "sha256:41744aa264f3c182e720d5bed3d9ecb552dbc9e97422bad522bd658a5165e822"
}
